SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

$RMD
Medical/Dental Instruments
Health Care
Get the next $RMD alert in real time by email
SC 13G/A 1 formsc13ga.htm FORM SC 13G/A WCM Investment Management: Form SC 13G/A - Filed by newsfilecorp.com

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

ResMed Inc.

(Name of Issuer)

 

Common

(Title of Class of Securities)

 

761152107

(CUSIP Number)

 

December 31, 2022

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 [X]  Rule 13d-1(b)

 [_]  Rule 13d-1(c)

 [_]  Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


SCHEDULE 13G

CUSIP No.           761152107


1

Names of Reporting Persons

WCM Investment Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)  [ ]
(b)  [ ]

3

Sec Use Only

 

4

Citizenship or Place of Organization

Delaware

Number of
Shares
Beneficially
Owned by Each
Reporting Person
With:

5

Sole Voting Power

3,832,642

6

Shared Voting Power

0

7

Sole Dispositive Power

3,832,642

8

Shared Dispositive Power

0

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,832,642

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

[ ]

11

Percent of class represented by amount in row (9)

2.6%

12

Type of Reporting Person (See Instructions)

IA



Item 1.

(a) Name of Issuer: ResMed Inc.

(b) Address of Issuer's Principal Executive Offices: 9001 Spectrum Center Blvd, San Diego, CA 92123 United States

Item 2.

(a) Name of Person Filing: WCM Investment Management, LLC

(b) Address of Principal Business Office or, if None, Residence:  281 Brooks Street, Laguna Beach, California 92651

(c) Citizenship: Delaware

(d) Title and Class of Securities: Common

(e) CUSIP No.: 761152107

Item 3.  If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) [_] Broker or dealer registered under Section 15 of the Act;

(b) [_] Bank as defined in Section 3(a)(6) of the Act;

(c) [_] Insurance company as defined in Section 3(a)(19) of the Act;

(d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940;

(e) [X] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

(g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

(h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

(j) [_] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

(k) [_] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4. Ownership

(a) Amount Beneficially Owned:  3,832,642


(b) Percent of Class:  2.6%

(c) Number of shares as to which such person has:

 (i) Sole power to vote or to direct the vote: 3,832,642

 (ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of: 3,832,642

(iv) Shared power to dispose or to direct the disposition of: 0

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [    ].

Item 6. Ownership of more than Five Percent on Behalf of Another Person.

Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

Item 8. Identification and classification of members of the group.

Item 9. Notice of Dissolution of Group.

Item 10. Certifications.


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:  February 9, 2023

/s/ Signature

Name/Title David J. Joerger, Chief Compliance Officer

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

 

Get the next $RMD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RMD

DatePrice TargetRatingAnalyst
3/19/2025$280.00Overweight
Morgan Stanley
3/19/2025Overweight
Morgan Stanley
1/16/2025Buy
Goldman
1/10/2025$252.00Neutral
Piper Sandler
12/13/2024$250.00Hold
Stifel
9/24/2024$280.00Outperform
Robert W. Baird
9/18/2024$180.00Peer Perform → Underperform
Wolfe Research
9/4/2024Buy → Hold
Needham
More analyst ratings

$RMD
Press Releases

Fastest customizable press release news feed in the world

See more
  • New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

    SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in The Lancet Respiratory Medicine, demonstrating that CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea (OSA). Analyzing data from over 1 million sleep apnea patients worldwide, the study provides the strongest evidence to date that CPAP therapy not only alleviates OSA symptoms but can also prolong life. OSA affects over one billion people worldwide,1 with over 80% of cases undiagnosed and untreated.2 This chron

    $RMD
    Medical/Dental Instruments
    Health Care
  • Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution

    SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a comprehensive brand evolution designed to unify its brand portfolio to serve more people and healthcare providers worldwide and reflect growing direct to consumer engagement. For 35 years, Resmed has pioneered innovations in respiratory therapy, including CPAP therapy and digital health solutions. The company's last major brand update in 2014 marked its shift to connectivity, introducing cloud-connected medical devices that revolutionized sleep apnea therapy. Today, Resmed is taking the next step –

    $RMD
    Medical/Dental Instruments
    Health Care
  • ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

    7 out of 10 employed respondents have called in sick at least once in their career due to poor sleep.18% of couples reported sleeping in separate rooms due to snoring and restlessness.Women report fewer quality sleep nights and more difficulties falling asleep than men. SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD)), a global health technology leader focused on sleep, breathing, and care delivered in the home, today unveiled the findings of its fifth annual Global Sleep Survey. With insights from 30,026 respondents across 13 markets, the study underscores a widespread global sleep crisis, with people losing an average of nearly three nights of restorative sleep

    $RMD
    Medical/Dental Instruments
    Health Care

$RMD
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$RMD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$RMD
SEC Filings

See more

$RMD
Leadership Updates

Live Leadership Updates

See more
  • Jan De Witte joins GHO Capital as Operating Partner

    Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

    $IART
    $RMD
    Medical/Dental Instruments
    Health Care
  • Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

    NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. "Incannex's

    $IXHL
    $RMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
  • ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board

    DelOrefice is the Chief Financial Officer at BD, one of the largest global MedTech companies in the worldBoard appointment brings over 30 years of strategic and operational finance expertise SAN DIEGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced it has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board, effective immediately. Mr. DelOrefice was appointed during ResMed's regularly scheduled board meeting on August 15, 2024, and will stand for re-election with the rest of ResMed's directors at its annual meeting on November 21, 2024. Mr. DelOrefice has also been appointed as a member of ResMed's board au

    $RMD
    Medical/Dental Instruments
    Health Care

$RMD
Financials

Live finance-specific insights

See more
  • ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025

    Year-over-year revenue grows 10%, operating profit up 52%, non-GAAP operating profit up 19%Operating cash flow of $309 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended December 31, 2024. Second Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 10% to $1.3 billion; up 10% on a constant currency basis Gross margin improved 300 bps to 58.6%; non-GAAP gross margin improved 230 bps to 59.2%Income from operations increased 52%; non-GAAP income from operations

    $RMD
    Medical/Dental Instruments
    Health Care
  • ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025

    SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the second quarter of fiscal year 2025 on Thursday, January 30, 2025, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: • Location:https://investor.resmed.com• Date:Thursday, January 30, 2025• Time:1:30 p.m. PST / 4:30 p.m. EST• International:London, Thursday, January 30, 2025, 9:30 p.m. GMT Sydney, Friday, January 31, 2025, 8:30 a.m. AEDT   Please no

    $RMD
    Medical/Dental Instruments
    Health Care
  • ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2025

    Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27%Operating cash flow of $326 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD))) today announced results for its quarter ended September 30, 2024. First Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 11% to $1.2 billion; up 11% on a constant currency basis Gross margin improved 420 bps to 58.6%; non-GAAP gross margin improved 320 bps to 59.2%Income from operations increased 34%; non-GAAP income from operation

    $RMD
    Medical/Dental Instruments
    Health Care

$RMD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more